当前位置: X-MOL 学术J. Med. Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Discovery of Novel Inhibitors of LpxC Displaying Potent in Vitro Activity against Gram-Negative Bacteria.
Journal of Medicinal Chemistry ( IF 7.3 ) Pub Date : 2019-12-24 , DOI: 10.1021/acs.jmedchem.9b01604
Jean-Philippe Surivet 1 , Philippe Panchaud 1 , Jean-Luc Specklin 1 , Stefan Diethelm 1 , Anne-Catherine Blumstein 1 , Jean-Christophe Gauvin 1 , Loïc Jacob 1 , Florence Masse 1 , Gaëlle Mathieu 1 , Azely Mirre 1 , Christine Schmitt 1 , Roland Lange 1 , Naomi Tidten-Luksch 1 , Carmela Gnerre 1 , Swen Seeland 1 , Charlyse Herrmann 1 , Peter Seiler 1 , Michel Enderlin-Paput 1 , Aengus Mac Sweeney 1 , Micha Wicki 1 , Christian Hubschwerlen 1 , Daniel Ritz 1 , Georg Rueedi 1
Affiliation  

UDP-3-O-((R)-3-hydroxymyristoyl)-N-glucosamine deacetylase (LpxC) is as an attractive target for the discovery and development of novel antibacterial drugs to address the critical medical need created by multidrug resistant Gram-negative bacteria. By using a scaffold hopping approach on a known family of methylsulfone hydroxamate LpxC inhibitors, several hit series eliciting potent antibacterial activities against Enterobacteriaceae and Pseudomonas aeruginosa were identified. Subsequent hit-to-lead optimization, using cocrystal structures of inhibitors bound to Pseudomonas aeruginosa LpxC as guides, resulted in the discovery of multiple chemical series based on (i) isoindolin-1-ones, (ii) 4,5-dihydro-6H-thieno[2,3-c]pyrrol-6-ones, and (iii) 1,2-dihydro-3H-pyrrolo[1,2-c]imidazole-3-ones. Synthetic methods, antibacterial activities and relative binding affinities, as well as physicochemical properties that allowed compound prioritization are presented. Finally, in vivo properties of lead molecules which belong to the most promising pyrrolo-imidazolone series, such as 18d, are discussed.

中文翻译:

发现对革兰氏阴性细菌具有体外活性的LpxC新型抑制剂。

UDP-3-O-((R)-3-羟基肉豆蔻酰基)-N-葡糖胺脱乙酰基酶(LpxC)是发现和开发新型抗菌药物的有吸引力的靶标,以解决由多重耐药革兰氏阴性菌产生的关键医疗需求细菌。通过对已知的甲基砜异羟肟酸酯LpxC抑制剂家族使用脚手架跳跃方法,鉴定了几个引发针对肠杆菌科细菌和铜绿假单胞菌的有效抗菌活性的命中系列。随后的铅到铅最优化,使用与铜绿假单胞菌LpxC结合的抑制剂的共晶体结构作为指导,导致发现了基于(i)异吲哚啉-1-酮,(ii)4,5-二氢-6H的多个化学系列-噻吩并[2,3-c]吡咯-6-酮和(iii)1,2-二氢-3H-吡咯并[1,2-c]咪唑-3-酮。合成方法 给出了抗菌活性和相对结合亲和力,以及允许化合物优先处理的理化性质。最后,讨论了属于最有前途的吡咯并-咪唑啉酮系列(例如18d)的铅分子的体内特性。
更新日期:2019-12-25
down
wechat
bug